[Personal experience with the use of 13-cis-retinoic acid in the therapy of severe forms of acne vulgaris].
The authors present the results of the study of the use of 13-cis-retinoic acid in the therapy of patients with a severe clinical form of acne. Twenty patients with a conglobate form of acne were included in the study. The drug was dosed in the initial phase of treatment at the dose of 0.5 mg/kg. During therapy the dose was reduced to 0.2 mg/kg depending on the clinical efficiency and appearance of unwanted effects. Therapy was conducted in the total duration of 16-20 weeks so that the patients received a mean drug dose of 0.31-0.60 mg/kg. The complete withdrawal of skin changes was registered in two patients (10%) after 12 weeks of therapy, in 15 patients (75%) after 16 weeks, and in 3 patients (15%) after 20 weeks of therapy. After the stop of drug action, the favorable effect was maintained from 2-12 months which was how long the patients were followed. The most frequently evidenced unwanted effects of therapy were dryness of the lip mucous membranes and skin. All unwanted therapy effects diminished or disappeared with drug dose decrease.
Poljacki
M
M
Medicinski fakultet, Klinika za dermatoveneroloske bolesti, Novi Sad.
Duran
V
V
Stojanović
S
S
D000152:Acne Vulgaris / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D015474:Isotretinoin / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male
D015474:Isotretinoin
Nasa iskustva u primeni 13-cis-retinoicne kiseline u terapiji teskih formi acne vulgaris.